11 September 2018 - - US-based biotechnology company Cavion, Inc has appointed Julia P. Gregory, MBA, as the company's new executive chair, the company said.

Julia Gregory joins Cavion with deep expertise and experience in the biopharmaceutical industry, having served as CEO of Five Prime Therapeutics and ContraFect Corp. and as executive vice president, Corporate Development and CFO of Lexicon Therapeutics.

She is currently a member of the boards of directors of numerous biotech companies, including Biohaven Therapeutics Holding Company, Sosei Heptares Group and IMV, Inc. Gregory is also chairman and CEO of the biotechnology financial and management advisory firm, Isometry Advisors, Inc.

During her tenure in the industry, she has raised more than USD 1.5bn across all stages of the business cycle and structured creative strategic alliances and transactions with pharmaceutical industry leaders, including GlaxoSmithKline, Bristol-Myers Squibb, Takeda, Genentech (now Roche), and Human Genome Sciences (now GSK).

Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.

The company's portfolio of calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures.